Patents by Inventor Robert W. Siegel
Robert W. Siegel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190162726Abstract: The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.Type: ApplicationFiled: December 31, 2018Publication date: May 30, 2019Inventors: David J. Hawksworth, Robert W. Siegel, Bryan C. Tieman, Bailin Tu, Susan E. Brophy, Dinesh O. Shah, Joan D. Tyner, Robert N. Ziemann
-
Patent number: 10215754Abstract: The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.Type: GrantFiled: October 6, 2016Date of Patent: February 26, 2019Assignee: Abbott LaboratoriesInventors: Susan E. Brophy, David J. Hawksworth, Dinesh O. Shah, Robert W. Siegel, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann
-
Publication number: 20170023568Abstract: The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.Type: ApplicationFiled: October 6, 2016Publication date: January 26, 2017Inventors: Susan E. Brophy, David J. Hawksworth, Dinesh O. Shah, Robert W. Siegel, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann
-
Patent number: 9482667Abstract: The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.Type: GrantFiled: April 14, 2015Date of Patent: November 1, 2016Assignee: ABBOTT LABORATORIESInventors: Susan E. Brophy, David J. Hawksworth, Dinesh O. Shah, Robert W. Siegel, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann
-
Patent number: 9453073Abstract: Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to glucagon. These antibodies are useful in immunoassays of glucagon levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting glucagon levels, and for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients in which glucagon signaling is implicated in pathogenesis.Type: GrantFiled: November 27, 2012Date of Patent: September 27, 2016Assignee: Eli Lilly and CompanyInventors: David Edward Watson, Robert W. Siegel, Nan Jia, John Harrison Sloan
-
Publication number: 20150212083Abstract: The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.Type: ApplicationFiled: April 14, 2015Publication date: July 30, 2015Inventors: Susan E. Brophy, David J. Hawksworth, Dinesh O. Shah, Robert W. Siegel, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann
-
Patent number: 9073984Abstract: The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.Type: GrantFiled: January 19, 2012Date of Patent: July 7, 2015Assignee: ABBOTT LABORATORIESInventors: Susan E. Brophy, David J. Hawksworth, Dinesh O. Shah, Robert W. Siegel, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann
-
Publication number: 20140335096Abstract: Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to glucagon. These antibodies are useful in immunoassays of glucagon levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting glucagon levels, and for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients in which glucagon signaling is implicated in pathogenesis.Type: ApplicationFiled: November 27, 2012Publication date: November 13, 2014Inventors: David Edward Watson, Robert W. Siegel, Nan Jia, John Harrison Sloan
-
Patent number: 8846036Abstract: The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.Type: GrantFiled: December 5, 2008Date of Patent: September 30, 2014Assignee: Abbott LaboratoriesInventors: Larry G. Birkenmeyer, Suresh M. Desai, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Robert N. Ziemann, Frank C. Grenier, Ryan F. Workman, Lowell Tyner
-
Publication number: 20120122125Abstract: The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.Type: ApplicationFiled: January 19, 2012Publication date: May 17, 2012Applicant: ABBOTT LABORATORIESInventors: Susan E. Brophy, David J. Hawksworth, Dinesh O. Shah, Robert W. Siegel, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann
-
Patent number: 8022188Abstract: The present invention relates among other things to antibodies that immunospecifically bind to at least one agent of interest (e.g., an immunosuppressive agent), methods for producing such antibodies, and immunoassays that employ said antibodies. Additionally, the present invention also relates to methods for selecting an antibody for use in a diagnostic immunoassay and methods for selecting an antigen for use in a diagnostic immunoassay. The present invention further relates to the improvement of antibody recognition of an active parent drug in the presence of one or more of its major metabolites.Type: GrantFiled: April 23, 2007Date of Patent: September 20, 2011Assignee: Abbott LaboratoriesInventors: Robert W. Siegel, Joan D. Tyner, Terry Y. Nakagawa
-
Publication number: 20100227775Abstract: The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample.Type: ApplicationFiled: May 21, 2010Publication date: September 9, 2010Applicant: ABBOTT LABORATORIESInventors: Larry G. Birkenmeyer, Suresh M. Desai, Frank C. Grenier, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Ryan F. Workman, Robert N. Ziemann
-
Publication number: 20090269777Abstract: The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample.Type: ApplicationFiled: April 16, 2008Publication date: October 29, 2009Applicant: Abbott LaboratoriesInventors: Larry G. Birkenmeyer, Suresh M. Desai, Frank C. Grenier, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Lowell J. Tyner, Ryan F. Workman, Robert N. Ziemann
-
Publication number: 20090263894Abstract: The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.Type: ApplicationFiled: December 5, 2008Publication date: October 22, 2009Applicant: ABBOTT LABORATORIESInventors: Larry G. Birkenmeyer, Suresh M. Desai, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann
-
Publication number: 20090203037Abstract: The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.Type: ApplicationFiled: December 23, 2008Publication date: August 13, 2009Applicant: Abbott LaboratoriesInventors: Susan E. Brophy, David J. Hawksworth, Dinesh O. Shah, Robert W. Siegel, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Lowell J. Tyner, Robert N. Ziemann
-
Publication number: 20090124022Abstract: The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.Type: ApplicationFiled: April 16, 2008Publication date: May 14, 2009Applicant: Abbott LaboratoriesInventors: Larry G. Birkenmeyer, Suresh M. Desai, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann, Lowell J. Tyner
-
Publication number: 20090123946Abstract: The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample.Type: ApplicationFiled: December 5, 2008Publication date: May 14, 2009Applicant: ABBOTT LABORATORIESInventors: Larry G. Birkenmeyer, Suresh M. Desai, Frank C. Grenier, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Ryan F. Workman, Robert N. Ziemann, Lowell J. Tyner
-
Publication number: 20080176756Abstract: The present invention relates among other things to antibodies that immunospecifically bind to at least one agent of interest (e.g., an immunosuppressive agent), methods for producing such antibodies, and immunoassays that employ said antibodies. Additionally, the present invention also relates to methods for selecting an antibody for use in a diagnostic immunoassay and methods for selecting an antigen for use in a diagnostic immunoassay. The present invention further relates to the improvement of antibody recognition of an active parent drug in the presence of one or more of its major metabolites.Type: ApplicationFiled: April 23, 2007Publication date: July 24, 2008Inventors: Robert W. Siegel, Joan D. Tyner, Terry Y. Nakagawa
-
Patent number: 6500652Abstract: The invention provides antiviral compounds and compositions comprising a viral specific oligonucleotide. Also provided are methods to inhibit or treat viral infections with the compounds or compositions of the invention.Type: GrantFiled: March 25, 1999Date of Patent: December 31, 2002Assignee: Advanced Research and Technology Institute, Inc.Inventors: C. Cheng Kao, Robert W. Siegel
-
Publication number: 20020103143Abstract: The invention provides antiviral compounds and compositions comprising a viral specific oligonucleotide. Also provided are methods to inhibit or treat viral infections with the compounds or compositions of the invention.Type: ApplicationFiled: March 25, 1999Publication date: August 1, 2002Inventors: C. CHENG KAO, ROBERT W. SIEGEL